Financial Data and Key Metrics Changes - Revenues for the nine months ended December 31, 2025, totaled $887,000, a decrease of 2% from the same year-ago period [17] - Gross profit for the first nine months was $551,500, or 62.2% of revenues, down from 89% of revenues in the same period a year ago [19] - Net loss for the first nine months was $7.5 million, or 27 cents per share, compared to a net loss of $6 million, or 30 cents a share for the same year-ago period [22] - Total operating expenses decreased 2% to $6.7 million compared to the same year-ago period [21] - Current assets totaled $1.4 million, while current liabilities significantly reduced to $980,000 from $4.2 million a year ago [23][24] Business Line Data and Key Metrics Changes - Sales of Spryng products totaled $400,800, while sales of PrecisePRP products totaled $486,000, indicating a shift in sales mix [17] - The decrease in revenues was primarily due to a decline in Spryng product sales, offset by an increase in PrecisePRP sales [18] - The company plans to re-implement special promotions to incentivize distributors and veterinary clinics to improve Spryng sales [18] Market Data and Key Metrics Changes - The Canadian animal healthcare market is projected to grow at a CAGR of 6.8% to exceed $4.4 billion by 2031 [25] - The European animal health market is estimated at over $16.6 billion today and is projected to grow at a CAGR of 8.6% to $34.8 billion by 2033 [15] Company Strategy and Development Direction - The company is focusing on creating rapid growth and market expansion opportunities, including strong recurring revenues [2] - Strategic alliances with partners like Digital Landia aim to enhance the veterinary industry through innovative AI solutions [3] - The launch of PetVivo AI, an AI-powered software platform for veterinarians, is expected to provide a strong first-mover advantage [4] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, expecting continued sales momentum and market penetration for fiscal 2026 and beyond [31] - The company is in advanced discussions with an outside sales and marketing firm to enhance its distribution network [31] - Management highlighted the importance of educating customers on the combined benefits of Spryng and PrecisePRP to drive future sales [19] Other Important Information - The company appointed Josh Ruben to its board of directors, bringing extensive experience in healthcare and life sciences [16] - The partnership with Veterinary Growth Partners aims to promote Spryng and PrecisePRP products to over 7,300 veterinary clinics [8] Q&A Session Summary Question: Updates on getting on the NASDAQ listings - The company is working towards uplisting on the New York AMEX, contingent on stock price and market conditions [34] Question: Can you talk about the previous guidance given on last conference call? - Management indicated that previous guidance was around $2 million-$2.5 million for fiscal year, but recent sales trends have affected expectations [37][38] Question: Are you pushing out the uptick in sales? - Management clarified that the sales model has changed, and they are focusing on spreading sales more evenly across quarters [40] Question: Can you talk about the CapEx required for the rollout of the Digital Landia platform? - The onboarding process for veterinarians is streamlined, and CapEx is minimal as Digital Landia will handle most of the implementation [42][51] Question: Will PetVivo recognize revenues from the implementation of the veterinarian system? - Yes, the company expects to recognize revenues as veterinarians implement the system and benefit from cost savings [46] Question: Do you have expectations for revenues and PNL? - Management refrained from providing specific revenue guidance at this time [52][53]

Financial Data and Key Metrics Changes - Revenues for the nine months ended December 31, 2025, totaled $887,000, a decrease of 2% from the same period a year ago [17] - Gross profit for the first nine months was $551,500, or 62.2% of revenues, down from $812,000, or 89% of revenues in the same period a year ago [19] - Net loss for the first nine months was $7.5 million, or 27 cents per share, compared to a net loss of $6 million, or 30 cents per share for the same year-ago period [22] - Total operating expenses decreased 2% to $6.7 million compared to the same year-ago period [21] - Current assets totaled $1.4 million, while current liabilities significantly reduced to $980,000 from $4.2 million a year ago [23] Business Line Data and Key Metrics Changes - Sales of Spryng products totaled $400,800, while PrecisePRP products totaled $486,000, indicating a shift in sales mix [17] - The decrease in revenues was primarily due to a decline in Spryng sales, offset by an increase in PrecisePRP sales [18] - The company plans to re-implement special promotions to incentivize distributors and veterinary clinics to improve Spryng sales [18] Market Data and Key Metrics Changes - The Canadian animal healthcare market is projected to grow at a CAGR of 6.8% to exceed $4.4 billion by 2031 [25] - The European animal health market is estimated at more than $16.6 billion today and is projected to double to $34.8 billion by 2033, growing at a CAGR of 8.6% [14][15] Company Strategy and Development Direction - The company is focusing on creating rapid growth and market expansion opportunities, including strong recurring revenues [2] - Strategic alliances with partners like Digital Landia aim to enhance the veterinary industry through innovative AI solutions [3] - The launch of PetVivo AI, an AI-powered software platform for veterinarians, is expected to provide a strong first-mover advantage [4] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, expecting continued sales momentum and market penetration for the duration of fiscal 2026 and beyond [31] - The company is in advanced discussions with an outside sales and marketing firm to enhance its distribution network [31] - Management highlighted the importance of educating customers on the combined benefits of Spryng and PrecisePRP to drive future sales [19] Other Important Information - The company appointed Josh Ruben to its board of directors, bringing extensive experience in healthcare and life sciences [16] - The partnership with Veterinary Growth Partners aims to promote Spryng and PrecisePRP products to over 7,300 veterinary clinics [8] Q&A Session Summary Question: Updates on getting on the NASDAQ listings - The company is working towards listing on New York AMEX, with stock price being a factor in the timeline [34] Question: Previous guidance on revenue - Management indicated that previous guidance was around $2 million-$2.5 million for the fiscal year, but recent sales trends have affected expectations [37][38] Question: CapEx for the rollout of the Digital Landia platform - The onboarding of veterinarians will be part of the current clinics, with minimal CapEx required as Digital Landia will handle the system updates [42][51] Question: Revenue expectations from the implementation of the PetVivo.ai system - Management confirmed that revenues will be recognized from veterinarians implementing the system, which operates on a SaaS model [46][48]

Financial Data and Key Metrics Changes - Revenues for the nine months ended December 31, 2025, totaled $887,000, a decrease of 2% from the same year-ago period [17] - Gross profit for the first nine months totaled $551,500, or 62.2% of revenues, down from 89% of revenues in the same period a year ago [19] - Net loss for the first nine months was $7.5 million, or 27 cents per share, compared to a net loss of $6 million, or 30 cents a share for the same year-ago period [21] - Total liabilities decreased by 81% to $1 million on December 31, down from $5.1 million on March 31 [23] Business Line Data and Key Metrics Changes - Sales of Spryng products totaled $400,800, while sales of PrecisePRP products totaled $486,000, indicating a shift in sales mix [17] - The decrease in revenues was primarily due to a decline in Spryng product sales, offset by an increase in PrecisePRP sales [18] - Gross margins for the PrecisePRP product line were lower, impacting overall gross profit [19] Market Data and Key Metrics Changes - The Canadian animal healthcare market is projected to grow at a CAGR of 6.8% to exceed $4.4 billion by 2031 [24] - The European animal health market is estimated at over $16.6 billion today and is projected to double to $34.8 billion by 2033, growing at a CAGR of 8.6% [15] Company Strategy and Development Direction - The company is focusing on creating strong recurring revenues and market expansion opportunities through new product launches and strategic partnerships [2] - A new AI-powered software as a service platform, PetVivo AI, is being launched to enhance veterinary practices and reduce customer acquisition costs [4][5] - The company is advancing its product pipeline, including new functional biomaterials for regenerative applications [26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued sales momentum and market penetration for the remainder of fiscal 2026 and beyond [30] - The company is in advanced discussions with an outside sales and marketing firm to enhance its distribution network [30] - Management highlighted the importance of educating customers on the combined use of Spryng and PrecisePRP to drive future sales [18] Other Important Information - The company appointed Josh Ruben to its board of directors, bringing extensive experience in healthcare and life sciences [16] - The partnership with Digital Landia aims to address challenges in the veterinary industry and enhance customer engagement through AI technology [3] Q&A Session Summary Question: Updates on getting on the NASDAQ listings - The company is working towards uplisting on the New York AMEX, contingent on stock price and market conditions [33] Question: Can you talk about the previous guidance given on last conference call? - Management noted that previous guidance was not recalled, but acknowledged that sales were affected by changes in promotional strategies [36][38] Question: Can you discuss the CapEx required for the rollout of the Digital Landia platform? - The onboarding process for veterinarians is designed to be efficient, with minimal CapEx required from the company [41][50] Question: Will PetVivo recognize revenues from the implementation of the veterinarian system? - Yes, the company expects to recognize revenues as veterinarians implement the system [45] Question: Do you have expectations for revenues and PNL in the next year? - Management refrained from providing specific revenue guidance at this time [52]

Core Insights - PetVivo Holdings, Inc. reported financial and operational results for the third quarter and first nine months of fiscal year 2026, highlighting significant advancements in its product offerings and market strategies [1][40]. Fiscal Q3 Operational Highlights - The company launched PetVivo.ai, an AI-powered Software-as-a-Service platform for veterinarians, which has shown a 50% to 90% reduction in customer acquisition costs, decreasing from $80-$400 to less than $43 per target [4][16]. - An exclusive 10-year white-label licensing agreement was signed with Digital Landia for the AgenticPet AI technology, aimed at addressing challenges in the veterinary industry, particularly for Gen Z pet parents [6][15]. - The company completed Stage B of a joint R&D project with PiezoBioMembrane, confirming the mass production capability of a combined product with therapeutic benefits for animals and humans [5][28]. Product Development and Market Expansion - Health Canada acknowledged PetVivo's Spryng with OsteoCushion Technology as a veterinary medical device, opening a new market opportunity in Canada, with plans for a commercial launch in Q3 2026 [8][34]. - The company is advancing its collaboration with Veterinary Growth Partners (VGP) to promote its products to over 7,300 veterinary clinics in the U.S. [26][27]. - PetVivo's products, including Spryng and PrecisePRP, have received favorable feedback from veterinarians, particularly for managing osteoarthritis in animals [33][31]. Financial Performance - For the quarter ended December 31, 2025, the company reported revenues of $286,108, with a gross profit of $144,712, leading to an operating loss of $2,191,455 [55]. - The net loss available to common stockholders for the same period was $2,316,455, translating to a net loss per share of $0.07 [55]. Future Outlook - The U.S. animal health market is projected to double to $11.3 billion by 2030, providing strong growth opportunities for PetVivo [38]. - The company is in advanced discussions with a sales and marketing firm to enhance its distribution network and market penetration [39].

Core Viewpoint - PetVivo Holdings, Inc. will hold a conference call on February 16, 2026, to discuss its fiscal third quarter results for the period ending December 31, 2025 [1][2]. Group 1: Conference Call Details - The conference call is scheduled for February 16, 2026, at 5:00 p.m. Eastern time [2]. - A toll-free dial-in number and conference ID are provided for participants [2]. - A replay of the conference call will be available through a webcast link [3]. Group 2: Company Overview - PetVivo Holdings, Inc. focuses on innovative medical devices and therapeutics for companion animals, leveraging human therapies for veterinary applications [4]. - The company has a portfolio of twelve patents and six trade secrets protecting its biomaterials and products [5]. - Key products include SPRYNG with OsteoCushion technology for joint-related afflictions and PrecisePRP, a first-in-class platelet-rich plasma product [5].

Core Insights - PetVivo.ai has launched a video to explain its AI-powered platform for veterinary practices, aiming to simplify communication and enhance understanding of its services [1][2][4] - The platform connects pet parents with veterinary practices through a two-sided ecosystem, utilizing 10 specialized AI agents to facilitate client acquisition and health tracking [3][6] Company Overview - PetVivo Holdings, Inc. operates in the biomedical device sector, focusing on innovative medical devices and therapeutics for companion animals [8] - The company leverages human therapies for animal treatment, aiming for a quicker market entry compared to pharmaceuticals [8] - PetVivo has a diverse product pipeline, including patented technologies for managing joint-related afflictions in animals [9] Product and Service Details - The platform features a freemium model, starting with a free tier, to engage veterinary practices and pet parents [6] - Key products include SPRYNG with OsteoCushion technology for joint management and PrecisePRP, a platelet-rich plasma product for veterinary use [9]

Core Insights - PetVivo.ai has launched an AI platform aimed at transforming the $150 billion pet care market by significantly reducing customer acquisition costs for veterinary practices [2][4][9] Group 1: Company Overview - PetVivo Holdings, Inc. is focused on commercializing innovative medical products and therapeutics for companion animals and horses [2][12] - The company has introduced PetVivo.ai, an AI-driven Software-as-a-Service (SaaS) platform that enhances its existing product portfolio [3][10] Group 2: Market Opportunity - The pet care industry exceeds $150 billion annually, with Gen Z and Millennial pet parents making up 57% of pet owners, who expect modern digital experiences [4][8] - There are approximately 30,000 veterinary practices in the U.S. and over 100,000 worldwide, indicating a large and under-digitized market for PetVivo.ai [8] Group 3: Product and Technology - PetVivo.ai utilizes nine specialized AI agents to connect veterinary practices with pet owners, improving lead generation and customer engagement [5][10] - The platform has demonstrated a customer acquisition cost of $42.53, significantly lower than the typical $80–$400 spent by veterinary practices [2][7] Group 4: Financial Metrics - In a beta program, the median practice acquired 47 new clients over six months, achieving a blended customer acquisition cost of $42.53 [5][7] - The platform offers a pricing model starting at $1,999 per month, with gross margins between 80% and 90% [7] Group 5: Competitive Advantages - PetVivo.ai holds a first-mover advantage in the AI-driven veterinary market, with no direct competitors and strong network effects [10] - The company has established relationships with 1,200 veterinary clinic distributors and plans to expand to over 7,000 [10] Group 6: Valuation Potential - The launch of PetVivo.ai is expected to transition the company from traditional medical device revenue multiples (1–2x) to AI SaaS multiples (15–30x), indicating potential valuation upside [9]

Core Insights - PetVivo Holdings, Inc. has launched PetVivo.ai, an AI platform aimed at transforming the $150 billion pet care market by significantly reducing customer acquisition costs for veterinary practices [1][3][4] - The company is shifting from traditional medical device sales to a high-margin AI Software-as-a-Service (SaaS) model, which offers recurring revenue and scalability [2][5] Industry Context - The pet care industry exceeds $150 billion annually, with Gen Z and Millennial pet owners making up 57% of all pet owners, who expect modern digital experiences [3] - Veterinary practices currently rely on outdated marketing methods, leading to high customer acquisition costs ranging from $80 to $400 per new client [3][4] Company Strategy - PetVivo.ai utilizes nine specialized AI agents to connect veterinary practices with engaged pet parents, generating qualified leads at a cost of $3 per pet parent, compared to traditional methods costing $15 to $45 [4][6] - The platform's beta program showed that the median practice acquired 47 new clients over six months at a blended customer acquisition cost of $42.53, achieving significant savings [4][6] Financial Metrics - The platform is expected to achieve gross margins of 80-90% and a lifetime value to customer acquisition cost (LTV/CAC) ratio of 25:1 [6] - Projections indicate that by Year 1, the company could reach $12 million in annual recurring revenue (ARR) with 500 practices, scaling to $360 million ARR with 10,000 practices by Year 5 [6] Market Opportunity - PetVivo.ai targets approximately 30,000 U.S. veterinary practices and over 100,000 globally, with strong scaling potential even under conservative adoption forecasts [5][6] - The launch is seen as a catalyst for re-evaluating the company's valuation, transitioning from traditional medical device revenue multiples of 1-2x to AI SaaS multiples of 15-30x [5][7] Competitive Advantages - PetVivo.ai holds a first-mover advantage with no direct AI competitors and strong two-sided network effects, supported by existing relationships with 1,200 veterinary clinic distributors [7] - Deep integrations with practice management systems are expected to facilitate adoption and reduce onboarding friction [7] Commercial Launch - Following successful beta testing, PetVivo.ai is now fully commercial with open sign-ups, offering a 14-day free trial and three pricing tiers [8]

Core Insights - PetVivo Holdings, Inc. is set to launch its veterinary platform in Q1 2026, supported by a comprehensive technical whitepaper from its AI technology partner, Digital Landia Holding Corp. [1][11] Technical Validation - The whitepaper confirms the technical foundation of PetVivo's exclusive 10-year licensing agreement, showcasing a multi-agent AI architecture that offers significant clinical and economic benefits for veterinary practices [2][9]. - The CEO of PetVivo emphasized that the whitepaper validates a production-ready AI framework with clinical utility and enterprise-grade architecture [3]. Framework Capabilities - The AI framework addresses key challenges in veterinary practices, including a 90% to 98% reduction in client acquisition costs and universal diagnostic assistance through nine specialized AI agents [4]. - The platform is designed to enhance access to the Gen Z market with a mobile-first consumer experience [4]. Intellectual Property - The whitepaper outlines five patent-pending innovations that protect the core functionality of the AgenticPet framework, providing competitive advantages under the licensing agreement [5]. Enterprise Architecture - The architecture is tailored for veterinary practices, featuring end-to-end encryption, blockchain audit trails, and HIPAA-aligned privacy frameworks, ensuring over 99.9% uptime reliability [6][7]. Distribution Network - PetVivo has an established distribution network, including a partnership with Veterinary Growth Partners, which has over 7,300 veterinary professional members, positioning the company for rapid deployment of the AgenticPet platform [7]. Strategic Rationale - The exclusive 10-year licensing agreement reflects PetVivo's confidence in the framework's competitive positioning and potential revenue streams, including B2B subscriptions and lead-generation fees [9]. Partnership Milestones - The publication of the whitepaper marks the third major milestone in the PetVivo–Digital Landia partnership, following the strategic alliance announcement and the exclusive licensing agreement [10]. Upcoming Launch - The technical foundation supports a dual-platform launch in Q1 2026, featuring both a B2C app and a B2B veterinary platform with AI diagnostic assistance [11].

Core Insights - PetVivo Holdings, Inc. reported a 51% increase in revenues for the second quarter of fiscal year 2026, totaling $303,000, driven by the introduction of the new product line PrecisePRP and expansion into the companion animal market [7][19][21] - The company has successfully entered the European market through a partnership with Nupsala Group, enhancing its distribution capabilities [6][16] - PetVivo's strategic collaborations, including with Digital Landia and Commonwealth Markets, are expected to enhance product adoption and market presence [10][17][18] Fiscal Q2 Financial Highlights - Revenues increased to $303,000, up 51% from the same quarter last year, marking a record for the second fiscal quarter [7][19] - Gross profit rose to $220,000, with a gross margin of 72.6%, an improvement from 63.8% in the previous quarter [20] - Operating loss increased to $2.1 million, while net loss rose to $3.0 million, reflecting increased sales and marketing expenses [21][22] Fiscal Q2 Operational Highlights - The company engaged additional distributors to support domestic and international expansion, with national distributor network sales increasing by 35% [7][19] - PetVivo's flagship product, Spryng with OsteoCushion Technology, has been adopted by over 1,200 veterinary clinics across the U.S. [17] - The company launched three new continuing education courses for veterinary professionals to enhance expertise in osteoarthritis and regenerative modalities [13] Strategic Partnerships and Innovations - A strategic partnership with Digital Landia aims to integrate AI technology into PetVivo's veterinary products, potentially reducing client acquisition costs significantly [10][18] - The collaboration with Commonwealth Markets has led to the integration of Spryng and PrecisePRP into care protocols for thoroughbred horses [17] - Ongoing research with PiezoBioMembrane is focused on developing biodegradable piezoelectric materials for regenerative applications [12][15] Financial Outlook - Management anticipates continued record growth for the full fiscal year ending March 31, 2026, driven by the expansion of Spryng and PrecisePRP [24][25] - The U.S. animal health market is projected to double to $11.3 billion by 2030, providing significant growth opportunities for PetVivo [18]